Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic study of mifamurtide in metastatic and/or recurrent osteosarcoma
NL-OMON42197Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Aug 2015
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mifamurtide in osteosarcoma (OS), sponsored by University of Oxford. Primary endpoints: Biological response and Radiological response. Started Aug 2015; status: active, not recruiting.
02
Drugs
mifamurtide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NL-OMON42197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42197.